PRostate Olaparib real World Evidence Study - PROWESs
Study identifier:D0817R00049
ClinicalTrials.gov identifier:NCT06031805
EudraCT identifier:N/A
CTIS identifier:N/A
Recruiting
Official Title
a French observational prospective multicenter study of adult patients treated in the real-life setting with olaparib for the treatment of metastatic castration-resistant prostate cancer
Medical condition
metastatic castration-resistant prostate cancer
Phase
N/A
Healthy volunteers
No
Study drug
-
Sex
Male
Estimated Enrollment
300
Study type
Observational
Age
18 Years - n/a
Date
Study Start Date: 11 Oct 2023
Estimated Primary Completion Date: 13 Oct 2028
Estimated Study Completion Date: 13 Oct 2028
Study design
Allocation: N/A
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -
Verification:
Verified 01 Nov 2024 by AstraZeneca
Sponsors
AstraZeneca
Collaborators
-
Inclusion and exclusion criteria
Loading...
Sort by status
- All Statuses
- Recruiting
- Not yet recruiting
- Recruiting complete
- Completed
- Other
No locations available
| Arms | Assigned Interventions |
|---|
